中国卒中杂志 ›› 2013, Vol. 8 ›› Issue (07): 565-.
他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组
收稿日期:
2013-07-02
出版日期:
2013-07-20
发布日期:
2013-07-20
基金资助:
北京市科委脑卒中急性期四项内科关键诊疗技术规范研究项目
(D101107049310005)
北京市科委缺血性卒中医疗服务标准的推广应用项目(Z121100005512016)
国家科技支撑计划项目
(2011BAI08B02)
Received:
2013-07-02
Online:
2013-07-20
Published:
2013-07-20
摘要:
【编者按】 卒中已成为中国人口死亡和致残的第一位原因,尽管脑血管病的诊疗技术不断提高,但缺血性卒中的病死率、复发率和致残率仍居高不下,危险因素的全面管理对减少复发和残疾至关重要。血脂异常是公认的缺血性卒中/短暂性脑缺血发作(transient ischemic attack,TIA)的可控危险因素之一,为了更好地指导神经科医师的临床实践,本刊组织我国部分神经科专家,在参考旧版《他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识》(以下简称共识)基础上[1],全面复习他汀相关最新文献,结合中国国情和临床现状,制定更新版《他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识》,并附以研究证据等级及推荐强度(表1[2]),以期指导神经科医师合理地使用他汀类药物,科学地防治缺血性卒中/TIA。
他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识[J]. 中国卒中杂志, 2013, 8(07): 565-.
Expert Consensus Group of Statins for Prevention and Treatment of Ischemic. Expert Consensus on Statins for Prevention and Treatment of Ischemic Stroke/Transient Ischemic Attack[J]. Chinese Journal of Stroke, 2013, 8(07): 565-.
1 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发作的专家共识(更新版)[J]. 中华内科杂志, 2008, 47:873-875.2 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南2010[J]. 中华神经科杂志, 2010, 43:146-153.3 Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010:findings from the Global Burden of Disease Study 2010[J]. Lancet, 2013, 381:1987-2015.4 陈竺. 全国第三次死因回顾性抽样调查报告[M]. 北京:中国协和医科大学出版社, 2008:10-17.5 Liu M, Wu B, Wang WZ, et al. Stroke in China:epidemiology, prevention, and management strategies[J]. Lancet Neurol, 2007, 6:456-464.6 The World Bank. Toward a Healthy and Harmonious Life in China:Stemming the Rising Tide of Non-Communicable Diseases[EB/OL]. (2011-07-25)[2013-02-26]. http://www.worldbank.org/content/dam/Worldbank/document/NCD_report_en.pdf.7 Xu G, Ma M, Liu X, et al. Is there a stroke belt in China and why[J]. Stroke, 2013, 44:1775-1783.8 Liu L, Wang D, Wong KS, et al. Stroke and stroke care in China:huge burden, significant workload, and a national priority[J]. Stroke, 2011, 42:3651-3654.9 Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National Stroke Registry (CNSR)[J]. Stroke, 2011, 42:1658-1664.10 Wang Y, Xu J, Zhao X, et al. Association of hypertension with stroke recurrence depends on ischemic stroke subtype[J]. Stroke, 2013, 44:1232-1237.11 Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980:systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants[J]. Lancet, 2011, 377:578-586.12 Yang W, Xiao J, Yang Z, et al. Serum lipids and lipoproteins in Chinese men and women[J]. Circulation, 2012, 125:2212-2221.13 李立明, 饶克勤, 孔灵芝, 等. 中国居民2002年营养与健康状况调查[J]. 中华流行病学杂志, 2005, 26:478-484.14 蒋立新, 李希, 李静, 等. 中国动脉粥样硬化性缺血性脑卒中患者他汀类药物应用现状调查[J]. 中华流行病学杂志, 2010, 31:925-928.15 中华医学会神经病学分会脑血管病学组"卒中一级预防指"撰写组. 中国卒中一级预防指南2010[J]. 中华神经科杂志, 2011, 44:282-288.16 中国医师协会心血管内科医师分会《中华内科杂志》编辑委员会. 心血管疾病一级预防中国专家共识[J]. 中华内科杂志, 2010, 49:174-185.17 Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias:The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J]. Atherosclerosis, 2011, 217:3-46.18 Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. J Am Coll Cardiol, 2004, 44:720-732.19 Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J]. Stroke, 2004, 35:2902-2909.20 European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008[J]. Cerebrovasc Dis, 2008, 25:457-507.21 Naci H, Brugts JJ, Fleurence R, et al. Comparative effects of statins on major cerebrovascular events:a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials[J]. QJM, 2013, 106:299-306.22 Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with Atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial[J]. Lancet, 2003, 361:1149-1158.23 Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial[J]. Lancet, 2004, 364:685-696.24 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005, 352:1425-1435.25 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359:2195-2207.26 Everett BM, Glynn RJ, MacFadyen JG, et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein:Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin (JUPITER)[J]. Circulation, 2010, 121:143-150.27 Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke:the Atherosclerosis Risk in Communities (ARIC) study[J]. Am J Epidemiol, 2000, 151:478-487.28 Yang EY, Chambless L, Sharrett AR, et al. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study[J]. Stroke, 2012, 43:103-108.29 Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness:a systematic review and meta-analysis[J]. Circulation, 2007, 115:459-467.30 Mathiesen EB, Johnsen SH, Wilsgaard T, et al. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke:a 10-year follow-up of 6584 men and women:the Tromsø Study[J]. Stroke, 2011, 42:972-978.31 Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis[J]. Nature, 2008, 451:904-913.32 Wasserman BA, Sharrett AR, Lai S, et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI:the multi-ethnic study of atherosclerosis (MESA)[J]. Stroke, 2008, 39:329-335.33 Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis:the METEOR Trial[J]. JAMA, 2007, 297:1344-1353.34 Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP):a prospective, randomised, double-blind trial[J]. Lancet, 2001, 357:577-581.35 Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[J]. JAMA, 2004, 291:1071-1080.36 Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J]. JAMA, 2006, 295:1556-1565.37 Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome:demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event:the ESTABLISH Study[J]. Circulation, 2004, 110:1061-1068.38 Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease[J]. Circulation, 2001, 104:387-392.39 Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis[J]. Endocr Pract, 2012, 18:1-78.40 Wong KS, Ng PW, Tang A, et al. Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients[J]. Neurology, 2007, 68:2035-2038. 41 Wong KS, Huang YN, Gao S, et al. Intracranial stenosis in Chinese patients with acute stroke[J]. Neurology, 1998, 50:812-813.42 Jeng JS, Tang SC, Liu HM, et al. Epidemiology, diagnosis and management of intracranial atherosclerotic disease[J]. Expert Rev Cardiovasc Ther, 2010, 8:1423-1432.43 Huang HW, Guo MH, Lin RJ, et al. Prevalence and risk factors of middle cerebral artery stenosis in asymptomatic residents in Rongqi Country, Guangdong[J]. Cerebrovasc Dis, 2007, 24:111-115.44 Bae HJ, Lee J, Park JM, et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics[J]. Cerebrovasc Dis, 2007, 24:355-360.45 Kim DE, Kim JY, Jeong SW, et al. Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis:a prospective multicenter study[J]. Stroke, 2012, 43:1824-1830.46 Tan TY, Kuo YL, Lin WC, et al. Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis[J]. J Neurol, 2009, 256:187-193.47 Arenillas JF. Intracranial atherosclerosis:current concepts[J]. Stroke, 2011, 42:S20-S23.48 Ní Chróinín D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke:the North Dublin Population Stroke Study[J]. Stroke, 2011, 42:1021-1029.49 Cappellari M, Deluca C, Tinazzi M, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study[J]. J Neurol Sci, 2011, 308:128-134.50 Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival[J]. Stroke, 2012, 43:147-154.51 Ní Chróinín D, Asplund K, Asberg S, et al. Statin therapy and outcome after ischemic stroke:systematic review and meta-analysis of observational studies and randomized trials[J]. Stroke, 2013, 44:448-456.52 Fisher M, Moonis M. Neuroprotective effects of statins:evidence from preclinical and clinical studies[J]. Curr Treat Options Cardiovasc Med, 2012, 14:252-259.53 中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2010[J]. 中华神经科杂志, 2010, 43:154-159.54 Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med, 2006, 355:549-559.55 Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes[J]. Stroke, 2009, 40:1405-1409.56 Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women:secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study[J]. Stroke, 2008, 39:2444-2448.57 Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack[J]. Neurology, 2009, 72:688-694.58 Amarenco P, Goldstein LB, Callahan AR, et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Atherosclerosis, 2009, 204:515-520.59 Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis:a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Stroke, 2008, 39:3297-3302.60 Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome:secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Arch Neurol, 2011, 68:1245-1251.61 Mascitelli L, Goldstein MR. Statins after ischemic stroke of undetermined etiology in young adults[J]. Neurology, 2011, 77:1931.62 Fang WT, Li HJ, Zhang H, et al. The role of statin therapy in the prevention of atrial fibrillation:a meta-analysis of randomized controlled trials[J]. Br J Clin Pharmacol, 2012, 74:744-756.63 Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J]. Stroke, 2011, 42:227-276.64 Amarenco P, Goldstein L B, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack:the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial[J]. Stroke, 2007, 38:3198-3204.65 Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia:systematic review and meta-analysis[J]. Curr Med Res Opin, 2011, 27:1191-1210.66 Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial[J]. Lancet, 2011, 377:2181-2192.67 Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study[J]. Neurology, 2008, 70:2364-2370.68 Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage:a retrospective cohort study[J]. Arch Neurol, 2012, 69:39-45.69 Martinez-Ramirez S, Delgado-Mederos R, Marín R, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke:results from a case-control study and a meta-analysis[J]. J Neurol, 2012, 259:111-118.70 Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J]. Lancet, 2010, 375:735-742.71 Preiss D, Seshasai S R, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis[J]. JAMA, 2011, 305:2556-2564.72 U.S. Food and Drug Administration. FDA Drug Safety Communication:Important safety label changes to cholesterol-lowering statin drugs[EB/OL]. (2012-07-03)[2013-05-09]. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.73 Waters DD, Ho JE, Demicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin:results from 3 large randomized clinical trials[J]. J Am Coll Cardiol, 2011, 57:1535-1545.74 Ridker PM, Pradhan A, Macfadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial[J]. Lancet, 2012, 380:565-571.75 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2010年版)[EB/OL]. 中国医学前沿杂志(电子版), 2011, 3:54-109.76 American Diabetes Association. Standards of medical care in diabetes--2010[J]. Diabetes Care, 2010, 33:S11-S61.77 中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35:390-419.78 Garcia RL, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes:a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins[J]. Pharmacoepidemiol Drug Saf, 2010, 19:1218-1224.79 Rosenson RS. Current overview of statin-induced myopathy[J]. Am J Med, 2004, 116:408-416.80 Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy:current knowledge, emerging challenges and potential solutions[J]. Pharmacogenomics, 2012, 13:579-954.81 Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis[J]. Am J Med, 2006, 119:400-409.82 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins:an update[J]. Fundam Clin Pharmacol, 2005, 19:117-125.83 血脂异常老年人使用他汀类药物中国专家共识组. 血脂异常老年人使用他汀类药物中国专家共识[J]. 中华内科杂志, 2010, 49:535-542.84 European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J]. Eur Heart J, 2011, 32:1769-1818. |
[1] | 马俊雯, 拜承萍. 血清炎症因子、脑血管反应性与短暂性脑缺血发作患者认知障碍的关系 [J]. 中国卒中杂志, 2022, 17(12): 1314-1320. |
[2] | 鲁燕, 杨保荣, 黄向萍, 杨冠桂, 陈圣文, 李建荣, 曾小明. 县级医院急性缺血性卒中超时间窗经MRI筛选溶栓的病例对照研究 [J]. 中国卒中杂志, 2022, 17(12): 1321-1326. |
[3] | 楚悦琪, 周凯云, 王田燕, 王炯彬, 李真. 卒中后吞咽障碍应用耳穴压豆治疗效果的meta分析 [J]. 中国卒中杂志, 2022, 17(12): 1327-1334. |
[4] | 周甜甜, 苏文杰, 连松勇, 林友聪. 丰富环境对卒中后血管性痴呆患者认知功能的影响 [J]. 中国卒中杂志, 2022, 17(12): 1343-1349. |
[5] | 宋彦丽, 林杰, 武一平, 李晓晶, 刘改芬, 夏文静, 张玉英, 张晓林, 吕晨冉, 周红, 李凯, 薛斌, 陈玲玲, 张忠波, 彭晓. 邯郸市居民心脑血管病危险因素的流行现状及高血压知晓率、治疗率和控制率的影响因素研究 [J]. 中国卒中杂志, 2022, 17(12): 1360-1365. |
[6] | 吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371. |
[7] | 蒋林, 李靖. 基于知识图谱分析人工智能用于卒中研究的现状及趋势 [J]. 中国卒中杂志, 2022, 17(12): 1372-1380. |
[8] | 梁潇, 钱海兵. 水通道蛋白4与卒中后认知障碍的关系研究进展[J]. 中国卒中杂志, 2022, 17(12): 1385-1390. |
[9] | 吴晓莉, 刘丽旭. 肥胖对卒中预后的影响[J]. 中国卒中杂志, 2022, 17(12): 1391-1395. |
[10] | 伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170. |
[11] | 王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177. |
[12] | 闫然, 闵妍, 全柯华, 李子孝. 脑源性神经营养因子和血清素再摄取转运体编码基因甲基化与卒中预后的关系[J]. 中国卒中杂志, 2022, 17(11): 1178-1182. |
[13] | 崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188. |
[14] | 邓宇含, 刘爽, 王子尧, 汪雨欣, 刘宝花. 基于结构化数据和机器学习模型预测普通人群卒中发病风险的系统评价和meta分析 [J]. 中国卒中杂志, 2022, 17(11): 1189-1197. |
[15] | 刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||